Archive for 'Tag Archives: 'ULg''

Synolyne Pharma raises its capital by € 3.3 million and sets off to market its product against degenerative osteoarthritis

Synolyne Pharma raises its capital by € 3.3 million and sets off to market its product against degenerative osteoarthritis

  Updating on a story from 2012, the spin-off of ULg, Synolyne Pharma has raised € 3,3 million to pursue the development of its treatment against degenerative osteoarthritis and in addition, sign an agreement with KitoZyme [...]

Rosellini Scientific Benelux SA Joins Walloon Region Consortium to Help Develop Implant System for Glaucoma Treatment

Rosellini Scientific Benelux SA Joins Walloon Region Consortium to Help Develop Implant System for Glaucoma Treatment

An exciting new medtech player in Belgium’s Walloon Region – Rosellini Scientific Benelux SA (RSB) – joins the consortium to develop a novel implant system for treating and monitoring glaucoma. The 4-partner consortium, led by iSTAR [...]

Dr. Andrei Turtoï of the “Metastasis Research Lab” (ULg): laureate of the ASIP 2013 Experimental Pathologist-in-Training Award

Dr. Andrei Turtoï of the “Metastasis Research Lab” (ULg): laureate of the ASIP 2013 Experimental Pathologist-in-Training Award

Dr. Andrei Turtoï is the 2013 recipient of the prestigious “ASIP Experimental Pathologist-in-Training Award”, presented by the American Society for Investigative Pathology  (http://www.asip.org/awards/epit.cfm). The EPIT Award1 is presented to an ASIP trainee member who is a post-doctoral [...]

Mithra pharmaceuticals: making the most of its Belgian homeland with new Liège investment and creation of 160 jobs

Mithra pharmaceuticals: making the most of its Belgian homeland with new Liège investment and creation of 160 jobs

François Fornieri, founder and CEO of Mithra Pharmaceuticals and former manager of the year in 2011(Trends-Tendances), recently announced he will be making an important €40-50 million long-term investment in Liège that is expected to create 160 [...]

Bone Therapeutics completes a €7.7 Million Series D Fundraising round to further advance ongoing PREOB® Phase III clinical trials

Bone Therapeutics completes a €7.7 Million Series D Fundraising round to further advance ongoing PREOB® Phase III clinical trials

Following the approval of the pivotal phase III osteonecrosis trial of PREOB® last November (posted Nov. 9, 2012), Bone Therapeutics has just completed a €7.7 million Series D fundraising round. Of the raised funds, €6.1 million were [...]

TRASIS (Ans, Belgium) gets global recognition with development of the first GMP (Good Manufacturing Practice) universal radiosynthesis unit

TRASIS (Ans, Belgium) gets global recognition with development of the first GMP (Good Manufacturing Practice) universal radiosynthesis unit

Trasis, a Belgian company experienced in the development of innovative solutions for the radiopharmaceutical industry, has joined forces with four local University laboratories in an effort to identify new types of biomarkers and tracers for in [...]

Bone Therapeutics gets approval for pivotal phase III osteonecrosis trial in Europe and treats first patients with their Advanced Therapy Medicinal Product PREOB®

Bone Therapeutics gets approval for pivotal phase III osteonecrosis trial in Europe and treats first patients with their Advanced Therapy Medicinal Product PREOB®

After receiving clearance from the competent authorities in Europe for its phase III pivotal osteonecrosis* trial with their second generation Advanced Therapy Medicinal Product (ATMP), PREOB®, bone regenerative medicine company Bone Therapeutics recently announced that their [...]

100th spin-off of the University of Liège, SYNOLYNE SA (Liège, Belgium), develops patented chitosan-based hydrogel to wipe out arthritis.

100th spin-off of the University of Liège, SYNOLYNE SA (Liège, Belgium), develops patented chitosan-based hydrogel to wipe out arthritis.

SYNOLYNE SA, the new spin-off of Liège University and spin-out of Kitozyme SA, is specialized in the research, development and marketing of a chitosan-based hydrogel with mechanical and biological properties designed to protect the cartilage and [...]

Arlenda S.A. takes a step outside Europe announcing Arlenda Inc. as their U.S. subsidiary.

Arlenda S.A. takes a step outside Europe announcing Arlenda Inc. as their U.S. subsidiary.

In the hotly competitive pharmaceutical sector, Arlenda SA(Spin-off – University of Liège, Belgium) is challenging their ability to create a space for themselves on the US market. In November 2011, Bruno Boulanger (CEO, Arlenda SA), and [...]

The power of partnership: Baxter and BioWin find new approach for supporting innovation and scientific excellence

The power of partnership: Baxter and BioWin find new approach for supporting innovation and scientific excellence

In an innovative approach to partnering, Baxter’s European R & D center in Belgium and BioWin, have come together to host a first-of-its-kind networking event aimed at creating new partnerships opportunities focusing on developing innovation. The [...]